XmAb-2513
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP) . XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research[1].
Product Specifications
UNSPSC
12352100
Target
TNF Receptor
Related Pathways
Apoptosis
Field of Research
Cancer
References & Citations
[1]Lawrence C E, et al. XmAb™ 2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies[J]. 2007.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
TNFRSF8/CD30
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470276-500 1x 500 µL
TAG-72 / CA72.4 (B72.3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042711-500 1x 500 µL
Carboxypeptidase A1 / CPA1 (Pancreatic Cancer Marker) (CPA1/2711), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042375-100 1x 100 µL
Cytokeratin 14 (KRT14) (Squamous Cell Marker) (KRT14/2375), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740419-100 1x 100 µL
Transglutaminase II (TGM2/419), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details